학술논문
Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
Document Type
Article
Author
Betge, Johannes; Barat, ana; Murphy, Verena; Hielscher, Thomas; Van Grieken, Nicole C.; Belle, Sebastian; Zhan, Tianzuo; Härtel, Nicolai; Kripp, Melanie; Bacon, Orna; Cordes, Martijn; Kay, Elaine W.; Verheul, Henk M.W.; Neerincx, Maarten; Hennessy, Bryan; Hofheinz, Ralf D.; Gaiser, Timo; Ylstra, Bauke; Prehn, Jochen H.M.; Lambrechts, Diether
Source
Subject
*COLON cancer treatment
*COMBINATION drug therapy
*BEVACIZUMAB
*EUROPEANS
*SURVIVAL analysis (Biometry)
*HEALTH
*
*
*
*
*
Language
ISSN
0012-2823
Abstract
Background/Aims: This study is aimed at analyzing the survival rates and prognostic factors of stage IV colorectal cancer patients from 3 European cohorts undergoing combination chemotherapy with bevacizumab. Methods: Progression free-survival (PFS) and overall survival (OS) were analyzed in 172 patients using the Kaplan–Meier method and uni- and multivariable Cox proportional hazards regression models. Results: The median PFS was 9.7 and the median OS 27.4 months. Patients treated at centers in Germany (n = 97), Ireland (n = 32), and The Netherlands (n = 43) showed a median PFS of 9.9, 9.2, and 9.7 months, OS of 34.0, 20.5, and 25.1 months, respectively. Patients >65 years had a significantly shorter PFS (9.5 vs. 9.8 months) but not OS (27.4 vs. 27.5 months) than younger patients. High tumor grade (G3/4) was associated with a shorter PFS, T4 classification with both shorter PFS and OS. Fluoropyrimidine (FP) chemotherapy backbones (doublets and single) had comparable outcomes, while patients not receiving FP backbones had a shorter PFS. In multivariable analysis, age and non-FP. [ABSTRACT FROM AUTHOR]